drugset / Trial / NCT01602302
Ultrasound and Withdrawal of Biological DMARDs in Rheumatoid Arthritis
NaSingle-groupOpen-labelTreatment
Summary
biological DMARDs may be stopped in Rheumatoid Arthritis (RA) patients treated with a combination of synthetic DMARD plus bDMARDs which are in persistent clinical remission. The research question of this study is, whether musculoskeletal sonography is a useful biomarker predicting a disease flare after cessation of bDMARD therapy.
Timeline
- Start
- 2012-06
- Primary completion
- 2020-11-19
- Completion
- 2020-11-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abatacept | Other / unclassified | — | — |
| Subject | Adalimumab | Monoclonal antibody | — | — |
| Subject | Certolizumab | Protein / enzyme biologic | — | — |
| Subject | Etanercept | Protein / enzyme biologic | — | — |
| Subject | Golimumab | Monoclonal antibody | — | — |
| Subject | Infliximab | Monoclonal antibody | — | — |
| Subject | Tocilizumab | Monoclonal antibody | — | — |